Protagonist Therapeutics, Inc Increase (Decrease) in Deferred Revenue
Protagonist Therapeutics, Inc (PTGX) reported Increase (Decrease) in Deferred Revenue of $31.75 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-03-07
- Protagonist Therapeutics, Inc increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$9.99M.
- Protagonist Therapeutics, Inc increase (decrease) in deferred revenue for fiscal 2017 was $31.75M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|
| 2017-12-31 | -$9.99M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $31.75M 10-K · filed 2018-03-07 | |
| 2017-09-30 | $41.74M 10-Q · filed 2017-11-07 | ||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |